Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Masonic Cancer Center, University of Minnesota
Updated on 7 February 2023
stem cell transplantation
fludarabine
cyclophosphamide
immunodeficiency
bone marrow transplant
busulfan
melphalan
deficiency
cell transplantation
bone marrow procedure
alemtuzumab
mesna
langerhans cell histiocytosis
lymphoproliferative disorder
undernutrition
x-linked lymphoproliferative disease
allogeneic hematopoietic stem cell transplant
lymphohistiocytosis
wiskott-aldrich syndrome
lymphoproliferative disease
hemophagocytic lymphohistiocytosis
omenn's syndrome
treatment guideline
chronic granulomatous disease
chediak-higashi syndrome
cd40l
primary immune deficiencies
granulomatous disease
reticular dysgenesis
primary immunodeficiency
histiocytosis
severe combined immunodeficiency
omenn syndrome
griscelli syndrome
cd40 ligand

Summary

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Description

Based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans:

Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen

Details
Condition SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Treatment cyclophosphamide, Stem cell transplantation, busulfan, melphalan, MESNA, Alemtuzumab 0.3 mg, Fludarabine phosphate 40 mg, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg
Clinical Study IdentifierNCT01652092
SponsorMasonic Cancer Center, University of Minnesota
Last Modified on7 February 2023

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note